Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
about
Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksAbsorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study.Etoricoxib--preemptive and postoperative analgesia (EPPA) in patients with laparotomy or thoracotomy--design and protocolsEtoricoxib and the treatment of ankylosing spondylitis.Relative cardiovascular and gastrointestinal safety of non-selective non-steroidal anti-inflammatory drugs versus cyclo-oxygenase-2 inhibitors: implications for clinical practice.Clinical pharmacology of etoricoxib.Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis.Etoricoxib for arthritis and pain managementSynthesis of Diarylpyrazoles Containing a Phenylsulphone or Carbonitrile Moiety and their Chalcones as Possible Anti-Inflammatory Agents.Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathyPreoperative administration of etoricoxib in patients undergoing hip replacement causes inhibition of inflammatory mediators and pain reliefEvaluation of a single preoperative dose of etoricoxib for postoperative pain relief in therapeutic knee arthroscopy: a randomized trial.Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxibUsing pharmacokinetic principles to optimize pain therapy.Combination of etoricoxib and low-pressure pneumoperitoneum versus standard treatment for the management of pain after laparoscopic cholecystectomy: a randomized controlled trial.NSAIDs and opioids in management of fragility fractures.The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.Efficacy of celecoxib in the treatment of joint pain caused by advanced haemophilic arthropathy in adult patients with haemophilia A.Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib.Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib.Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.Effects of preemptive analgesia in laparoscopic cholecystectomy: a double-blind randomized controlled trial.Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion.Analgesics and Antipyretics
P2860
Q30629677-4131FF8C-84EE-4915-9AFA-51C9255999A3Q33596397-6EA9D7BC-0A7C-4831-A8CF-F841831C8325Q33934086-EDA29473-98DB-43F9-84B5-BEF7CAFA8777Q34466689-2DDE8EC9-E654-4FCC-85F8-9D8E5F12A029Q34556831-022933A0-EB45-4727-A689-9A0F5EAE3BD9Q34570225-F309CDF4-F4E7-45F1-B1B3-D5E9E0667AAEQ34610283-465A6E9E-38B5-40E4-B25F-66B2476B747CQ35166773-C28FB3F8-F2F1-4651-86D6-FEFBDE3FEFABQ35185323-EC0DEABF-EFD4-48C9-BB24-F54C3B51B2CFQ35849418-A54747C1-4967-427E-82BE-68874BA4B8A1Q36220369-112A7E20-E0F5-4B07-A2DB-D0E69886692CQ36563754-FCF8E13A-1957-46A6-A445-3C33E8E90541Q37175779-8D6F0A23-EF6C-4681-91E7-D5F2C440552CQ37785746-9540D6B5-6F65-4E54-9DFD-3A56C7C63B0BQ40514029-58D8D877-8C76-4383-86A0-BAB9AC51727DQ43657363-9243E17F-2CA2-491E-B8CC-2526BFBD697FQ45040968-17BDFF4B-E710-411F-94C1-B9C6E2099AAFQ45863072-D2EDD992-880F-44D9-9210-B9D31F9F3A30Q46152222-5095AB6C-CFFB-4D40-88D2-3B02EFCFB455Q46382423-7F292613-EE55-4C60-A005-C2B586EBF048Q46628463-5B97C1EF-3BF4-41C8-834E-89697CB686ECQ47372560-7A60A726-D8F4-4238-BB85-B84933CA10A1Q48347246-23739522-4D70-4F11-9AC8-BCA414C38D87Q53602109-F64C8CAC-F946-4EBE-A942-911D2F602E83Q56113559-A26CF673-71EE-4E96-BF9B-DF4B1B1BC39F
P2860
Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
@en
Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
@nl
type
label
Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
@en
Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
@nl
prefLabel
Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
@en
Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
@nl
P2093
P2860
P356
P1476
Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
@en
P2093
Aimee Dallob
Barry Gertz
Christopher J Hawkey
Howard Greenberg
John Wagner
Keith Gottesdiener
Lisa DeTora
Nancy Agrawal
Nicholas Wight
Paul De Schepper
P2860
P304
P356
10.1177/0091270003253703
P577
2003-06-01T00:00:00Z